S&P 500 Freddie Mac Fannie Mae

[Sheppy]

bankruts play pensi che la rilevano?

Non so ma deve esserci qualcosa sotto quando un’azione con un Q finale è al rialzo… non trovo news

 

[Sheppy]

DRL giovedi 8/8 fin/risultati abbastanza buoni

announced the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 reporting net income of $8.2 million, compared to a net income of $1.6 million for the comparable 2008 period

 

[Sheppy]

VCV guarda questa

Aastrom Biosciences (NASDAQ: ASTM - News) announced before the bell this morning that its Bone Repair Cells (BRCs) showed positive results in a compassionate use study. Patients in the study suffer from severe craniofacial defects. Dr. Jose Mendonca, Director of the Head and Neck Surgery Unit of Spain's Hospital POLUSA, called the outcome of the study "very satisfactory" in a press release. Dr. Mendosa continued, "We observed early bone formation in the afflicted areas that eventually resulted in a complete healing." Shares are flying by 27% on the news.

 

[carlito's way]

ragazzi troppo tardi per agire, ho comprato a 0.67 e ho venduto a 1.30 non male vero ?Credo che si possa ora risalire a short.Fatemi sapere a giorni i vostri earnings.

 

[carlito's way]

sto parlando naturalmente di freddy

 

[VIA COL VENTO]

astm potrebbe anche 0,512 in ordine

 

[Sheppy]

Mi devo assentarmi per un pò (visite)... a dopo (spero)

 

[VIA COL VENTO]

ciao sheppy

 

[Sheppy]

astm potrebbe anche 0,512 in ordine

qualche info su ASTM
Compassionate Use Patients in Spain Treated With Adult Stem Cell Therapy Demonstrate Jaw Bone Regeneration Enabling Dental Implants

ASTM a leading regenerative medicine company, today announced that results from compassionate use treatments using Aastrom's Bone Repair Cells (BRCs) in patients suffering from severe craniofacial defects were presented at the 2nd Annual Congress of Regenerative Medicine & Stem Cell in Dalian, China. BRCs are derived from a small sample of the patient's bone marrow that is processed using Aastrom's proprietary Tissue Repair Cell (TRC) technology to generate larger numbers of stem and early progenitor cells with enhanced therapeutic potential.

 

[VIA COL VENTO]

entrato astm 0,512